- Pharma
- 1 min read
Zydus Lifesciences gets USFDA nod for generic medication
Zydus has got the final approval from the US Food and Drug Administration (USFDA) to market Icosapent Ethyl Capsules in strengths of 0.5 g and 1 g, it said in a regulatory filing. The capsules are indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Read by
The company has got the final approval from the US Food and Drug Administration (USFDA) to market Icosapent Ethyl Capsules in strengths of 0.5 g and 1 g, it said in a regulatory filing.
The capsules are indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
As per IQVIA data, Icosapent Ethyl Capsules, 0.5 g and 1 g, had annual sales of USD 1,316 million in the US. Shares of the company were trading marginally higher at Rs 518.80 apiece on BSE.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions